Innate Killer Summit Europe 2023

The momentum of innate immune cell R and D is growing exponentially to harness innate immune responses and promote gold-standard allogeneic therapies. Now is the time to gather this fledgling community and build further collaboration at the centre of innovation: in Europe.

The Innate Killer Summit Europe gathers 80+ key European Gamma Delta T, NK, iNKT, neutrophil, and macrophage developers in October to chase the holy grail of efficacious, off-the-shelf, solid tumour immunotherapies through effective and scalable engineering, engager and combination strategies that promote safe, potent and persistent innate immune therapies following application.

Seize your chance to network with innate immune trailblazers from the likes of Sanofi, Takeda, Lift Biosciences, Mink Therapeutics, Affimed, Carisma Therapeutics, Arovella Therapeutics and receive 3-days of some of the best scientific and data driven case studies that will help propel your innate immune therapy into the clinic and beyond.

URLs:
Tickets: https://go.evvnt.com/1810491-2?pid=185
Brochure: https://go.evvnt.com/1810491-3?pid=185

Prices:
Industry Pricing - Conference + 2 Workshops: GBP 3097.00,
Industry Pricing - Conference + 1 Workshop: GBP 2648.00,
Industry Pricing - Conference Only: GBP 2199.00,
Academic Pricing -  Conference + 2 Workshops: GBP 2597.00,
Academic Pricing - Conference + 1 Workshop: GBP 2198.00,
Academic Pricing - Conference Only: GBP 1799.00,
Solution Providers - Conference + 2 Workshops: GBP 4397.00,
Solution Providers - Conference + 1 Workshop: GBP 3748.00,
Solution Providers - Conference Only: GBP 3099.00

Speakers: Alex Blyth | Chief Executive Officer | Lift Biosciences, Andre Kunert | Senior Principal Scientist | Kiadis Pharma, Anna-Karin Maltais | Chief Scientific Officer | XNK Therapeutics, Evren Alici | Head of Cell and Gene Therapy Group | Karolinska Institutet, François Gianelli  | Head of Regulatory and Quality | TreeFrog Therapeutics, Helgi Van De Velde | Vice President Head Hematologic Malignacies Strategies and Late Development Malignan | Sanofi, Joachim Koch | Vice President and Head Discovery Research and Translational Immunology | Affimed, Kate Rochlin | Chief Operating Officer | IN8Bio, Keith Sutton | Director of Pre-Clinical Development | Resolution Therapeutics, Marc van Dijk | Chief Scientific Officer | MiNK Therapeutics, Michelle Morrow | Senior Vice President, Head of Research | F-star Biotechnology Ltd., Nicolo Rigamonti | Immuno-Oncology Consultant | Independent, Rafet Basar | Assistant Professor | MD Anderson Cancer Center, Ramji Krishnan | Senior Vice President and Head of Technical Operations | Celularity, Robert Igarashi  | Head of Discovery and Pre-clinical Development | Sanofi, Sherly Mardiana | Senior Scientist | Charisma Therapeutics, Subhankar Mukhopadhyay  | Senior Lecturer and Associate professor - Innate Immunity and Regenerative Medicine |  King's College London

Time: 9:00 am to 4:25 pm